Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1999-03-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1073/PNAS.96.7.4143PMID 10097177PMCID PMC22434
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity-dependent neurotrophic factor (ADNF)

  2007cited by this paper
• Neuropeptides as growth and differentiation factors in general and VIP in particular

  2007cited by this paper
• Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide

  1999cited by this paper
• Short precursor shortens memory

  1997cited by this paper
• Alzheimer's disease. Short precursor shortens memory.

  1997cited by this paper
• Alzheimer transgenic mouse models come of age.

  1997cited by this paper
• Alzheimer's Disease--Genotypes, Phenotype, and Treatments

  1997cited by this paper
• Alzheimer's disease: genotypes, phenotypes, and treatments.

  1997cited by this paper
• Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease.

  1997cited by this paper
• Cognition-enhancing drugs in dementia: a guide to the near future.

  1997cited by this paper
• Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides

  1997cited by this paper
• Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity.

  1997cited by this paper
• Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor‐dependent mechanism

  1997cited by this paper
• Photoaffinity labeling analysis of the interaction of pituitary adenylate-cyclase-activating polypeptide (PACAP) with the PACAP type I receptor.

  1997cited by this paper
• The neurochemistry of Alzheimer's disease.

  1997cited by this paper
• A femtomolar-acting neuroprotective peptide.

  1996cited by this paper
• Molecules that protect: the defense of neurons and other cells.

  1996cited by this paper
• A paradigm for distinguishing the roles of mitogenesis and trophism in neuronal precursor proliferation.

  1996cited by this paper
• Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Potentiate the Glutamate-evoked Release of Arachidonic Acid from Mouse Cortical Neurons

  1996cited by this paper
• Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus

  1996cited by this paper
• Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.

  1996cited by this paper
• Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma

  1995cited by this paper
• Small Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses (*)

  1995cited by this paper
• Minimization of a Polypeptide Hormone

  1995cited by this paper
• Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice.

  1995cited by this paper
• Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

  1995cited by this paper
• Research trends in Alzheimer's disease.

  1994cited by this paper
• PACAP Functions as a Neurotrophic Factor a

  1994cited by this paper
• Alzheimer's disease: pathophysiology and the hope for therapy.

  1994cited by this paper
• Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.

  1994cited by this paper
• Multiple receptors for PACAP and VIP.

  1994cited by this paper
• Alzheimer's disease: pathophysiology and the hope for therapy.

  1994cited by this paper
• Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line.

  1993cited by this paper
• Processing of vasoactive intestinal peptide and transferrin in human cancerous colonic cells.

  1992cited by this paper
• Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research

  1992cited by this paper
• A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.

  1992cited by this paper
• An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

  1991cited by this paper
• Vasoactive intestinal polypeptide carboxy-terminal fragment, VIP(22-28), and other fragments of VIP, in the central nervous system of the rat.

  1989cited by this paper
• (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.

  1989cited by this paper
• Vasoactive intestinal peptide and electrical activity influence neuronal survival.

  1986cited by this paper
• Synthesis, conformational studies and biological activities of VIP and related fragments.

  1984cited by this paper
• Developments of a water-maze procedure for studying spatial learning in the rat.

  1984cited by this paper
• Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences.

  1984cited by this paper
• The vasoactive intestinal peptide (VIP): VI. The 17-norleucine analog of the sequence 14–28☆

  1974cited by this paper
• Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide.

  1973cited by this paper
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper

• Nanoparticles targeting the central circadian clock: Potential applications for neurological disorders.

  2025cites this paper
• From circadian sleep disruption to Neuroprotection: The potential of VIP/PACAP in Alzheimer’s disease treatment

  2024cites this paper
• Profiles of women in science: Illana Gozes, Professor Emerita of Clinical Biochemistry, Tel Aviv University

  2023influential citation
• Synthesis and evaluation of cerebroprotective activity of novel 6,7-dimethoxyquinazolin-4(3H)-one derivatives containing residues of amino acids and dipeptides

  2022cites this paper
• Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis

  2021cites this paper
• Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases

  2020cites this paper
• ADNP Regulates Cognition: A Multitasking Protein

  2018cites this paper
• The effects of vasoactive intestinal peptide in neurodegenerative disorders

  2017cites this paper
• Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy

  2016cites this paper
• PACAP, VIP, and ADNP: Autism and Schizophrenia

  2016cites this paper
• Design and Synthesis of Neurologically Active Glycopeptides for Neuroprotection and Antinociception

  2015cites this paper
• Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP)

  2012cites this paper
• Agnathan VIP, PACAP and Their Receptors: Ancestral Origins of Today's Highly Diversified Forms

  2012cites this paper
• Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.

  2011cites this paper
• Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

  2011cites this paper
• Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.

  2010cites this paper
• Peptide classification using optimal and information theoretic syntactic modeling

  2010cites this paper
• VIP–PACAP 2010: My Own Perspective on Modulation of Cognitive and Emotional Behavior

  2010cites this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cites this paper
• Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications

  2008cites this paper
• VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research

  2008cites this paper
• Select cognitive deficits in Vasoactive Intestinal Peptide deficient mice

  2008cites this paper
• Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects

  2007cites this paper
• Apolipoprotein E knockout mice as a model of behavioral dysfunction

  2007cites this paper
• Neonatal mice of the down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation

  2007cites this paper
• Novel analogs of VIP with multiple C-terminal domains.

  2007cites this paper
• From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP

  2007cites this paper
• NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

  2006cites this paper
• Neuroprotective effect of the stearic acid against oxidative stress via phosphatidylinositol 3-kinase pathway.

  2006cites this paper
• PACAP38 AND PACAP4-6 ARE NEUROPROTECTIVE THROUGH INHIBITION OF NADPH OXIDASE: POTENT REGULATORS OF MICROGLIA-MEDIATED OXIDATIVE STRESS

  2006cites this paper
• Novel extended and branched N-terminal analogs of VIP.

  2006cites this paper
• Biodistribution of liposome‐entrapped human gamma‐globulin

  2006cites this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 38 and PACAP4–6 Are Neuroprotective through Inhibition of NADPH Oxidase: Potent Regulators of Microglia-Mediated Oxidative Stress

  2006cites this paper
• VIP-and PACAP-Related Neuroprotection

  2006cites this paper
• Molecular Chaperones and Cell Signalling: Neuroendocrine Aspects of the Molecular Chaperones ADNF and ADNP

  2005cites this paper
• Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases.

  2005cites this paper
• Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress

  2005cites this paper
• Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.

  2004cites this paper
• Hydrophobic dipeptide Leu‐Ile protects against neuronal death by inducing brain‐derived neurotrophic factor and glial cell line‐derived neurotrophic factor synthesis

  2004cites this paper
• Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury.

  2004cites this paper
• Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update.

  2004cites this paper
• Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.

  2004cites this paper
• The Biological Significance of PACAP and PACAP Receptors in Human Tumors: From Cell Lines to Cancers

  2003cites this paper
• A three amino acid peptide, Gly-Pro-Arg, protects and rescues cell death induced by amyloid beta-peptide.

  2003cites this paper
• VIP as a trophic factor in the CNS and cancer cells.

  2003cites this paper
• VIP and drug design.

  2003cites this paper
• Peptides et compositions medicinales contenant ces peptides

  2003cites this paper
• Peptides as drug candidates against Alzheimer's disease

  2002influential citation
• Carbocyanin-markierte Derivate des vasoaktiven intestinalen Peptids fü die Tumordiagnostik

  2002cites this paper
• Comparative neuroprotective effects of preischemic PACAP and VIP administration in permanent occlusion of the middle cerebral artery in rats.

  2002cites this paper
• Neuroprotective peptide drug delivery and development: potential new therapeutics.

  2001cites this paper
• Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits

  2001cites this paper
• Neuropeptides in the therapy of Alzheimer's disease.

  2001cites this paper
• A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines

  2001cites this paper
• VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

  2001cites this paper
• A new concept in the pharmacology of neuroprotection

  2000cites this paper
• VIP‐derived sequences modified by N‐terminal stearyl moiety induce cell death: the human keratinocyte as a model

  2000cites this paper
• A Novel VIP Responsive Gene: Activity Dependent Neuroprotective Protein

  2000cites this paper
• Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

  2000cites this paper
• Characterization of glucagon-like peptide-1 receptor-binding determinants.

  2000cites this paper
• VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress

  2000influential citation
• VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells

  2000cites this paper
• Immunology of VIP: a review and therapeutical perspectives.

  2000cites this paper
• Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist

  2000cites this paper
• Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

  2000cites this paper
• Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.

  2000influential citation
• A novel peptide prevents death in enriched neuronal cultures.

  2000cites this paper